Search
apremilast (Otezla)
Indications:
- psoriasis [2]
- active psoriatic arthritis (adults) [1,2]
Contraindications:
- NOT recommended for plaque psoriasis (NICE)
Monitor:
- body weight (BMI)
- neuropsychiatric effects [2]
Adverse effects:
- diarrhea
- nausea
- headache
- depression
Mechanism of action:
- phosphodiesterase-4 inhibitor
General
phosphodiesterase-4 inhibitor
disease-modifying antirheumatic agent (DMARD)
dermatologic agent
References
- FDA News Release: March 21, 2014
FDA approves Otezla to treat psoriatic arthritis
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm390091.htm
- Medical Knowledge Self Assessment Program (MKSAP) 17, 18,
American College of Physicians, Philadelphia 2015, 2018.